Immix Biopharma (IMMX) Expected to Post Earnings on Friday

Immix Biopharma (NASDAQ:IMMX) is expected to post its Q3 2026 resultson Friday, November 6th. Analysts expect the company to post earnings of ($0.18) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, analysts expect Immix Biopharma to post ($0.76) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.

Immix Biopharma Stock Up 6.2%

Shares of NASDAQ:IMMX opened at $7.71 on Wednesday. Immix Biopharma has a fifty-two week low of $2.85 and a fifty-two week high of $15.10. The firm has a 50-day simple moving average of $10.78 and a 200 day simple moving average of $9.46. The company has a market cap of $551.57 million, a PE ratio of -8.76 and a beta of 0.29.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Mizuho set a $23.00 target price on Immix Biopharma in a research note on Thursday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, October 15th. HC Wainwright boosted their price objective on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a research note on Wednesday, September 30th. Finally, Needham & Company LLC increased their target price on Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immix Biopharma has an average rating of “Moderate Buy” and a consensus price target of $23.86.

About Immix Biopharma

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.

Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.

Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.